Virtual Challenging Case Clinic: B-Cell Lymphomas - Follicular Lymphoma
Release Date: December 23, 2020
Expiration Date: December 23, 2021
This activity is for clinicians who treat patients with indolent and aggressive B-cell lymphomas: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.
After completing this activity, participants should be better able to:
- Evaluate the best available evidence regarding treatment for marginal zone lymphoma
- Assess the implications of emerging clinical trial data regarding marginal zone lymphoma therapy approaches
- Develop strategies to address complicated marginal zone lymphoma cases
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chair, Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medicine
New York, New York
Consulting Fees: ADC Therapeutics, AstraZeneca, Bayer, Bristol-Myers Squibb Company, Epizyme, a Kite Gilead Company, MEI Pharma, Miltenyi Biotec, Regeneron, Roche/Genentech, Sutro Biopharma
Jonathon Cohen, MD, MS
Associate Professor of Medicine, Dept of Hematology & Medical Oncology
Co-Director, Lymphoma Program
Director, Infusion Services
Winship Cancer Institute of Emory University
Consulting Fees: Adicet Bio, Aptitude Health, Celgene Corporation, Cellectar Biosciences, Inc., Janssen Oncology, Kite, a Gilead Company, Seattle Genetics
Research Funding: AstraZeneca, BeiGene, BioInvent, Bristol Myers Squibb Company, Genentech, LAM, Novartis, Seattle Genetics, Takeda Pharmaceutical Company
Educational grant support provided by AstraZeneca, Bristol Myers Squibb, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.